Clinical trial
Efficacy and Safety In Poorly Controlled Type 2 Diabetics
NCT00044460 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00044460 |
|---|---|
| Title | Efficacy and Safety In Poorly Controlled Type 2 Diabetics |
| Official title | A 24-week Randomized, Double-Blind, Parallel-Group, Multicenter Study to Demonstrate the Efficacy and Safety of Two Different Rosiglitazone Dosing Regimens, 4mg OD and 8mg OD, in Poorly-Controlled Drug Naive Patients With Type 2 Diabetes Mellitus |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | rosiglitazone |
| Enrollment | 142 |
| Start date | May 1, 2002 |
| Primary completion | Apr 10, 2003 |
| Completion | Apr 10, 2003 |
| First posted | Aug 30, 2002 |
| Last update posted | Oct 9, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: